KAPA · Kairos Pharma, LTD.
$0.54
0.00 (-0.18%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has experienced recurring losses from operations since inception and incurred a net loss of $3,042 and used cash in operations of $2,048 during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$1.84M
Shares
3.39M
Volume · Oct 23
108.1K
Avg daily vol (38 sessions)
568.33K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.56
Open$0.54
Day$0.53–0.59
52W close$0.54–8.05
Avg vol 30d691K
Short int113K · 3.3% float · 1.0d
Short vol43%
DataSep 2024–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$5.80M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$2.63M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+24.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
3.3%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 19 · elevated
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−82%
below
Price vs 50-day avg
−63%
below
RSI (14)
19
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−68%
trailing
6-month return
−86%
trailing
YTD return
−89%
this year
Relative strength
−92%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+27% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.34% of float · ▼ -1.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
14 holders — near 2-yr high, broad support
Squeeze score
42
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
26.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−82%
Bearish
Price vs 50-day avg
−63%
Bearish
RSI (14)
19
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+27% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.34% of float · ▼ -1.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
14 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $8
vs 200-day avg -82%
vs 50-day avg -63%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KAPA
this stock
Kairos Pharma, LTD.
|
$1.84M | — | — | — | 3.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$133.55B | +15.6% | +46.2% | 30.7 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.33B | +4.3% | +20.8% | 20.3 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.90B | +578.5% | +4.3% | — | 7.7% |
|
CSLLY
Csl Ltd
|
$65.88B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KAPA | -7.1% | -67.5% | -85.8% | -66.0% | -88.8% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | -6.7% | -66.1% | -91.7% | -65.6% | -100.2% |